PITTSBURGH, Dec. 11, 2014 /PRNewswire/ -- Mylan Inc.
(Nasdaq: MYL) today announced the U.S. launch of its Methocarbamol
Injection USP, 100 mg/mL, packaged in 1,000 mg/10 mL single-dose
vials. This product is the generic version of Hikma Maple Ltd.'s
Robaxin®. Mylan received final approval from the U.S.
Food and Drug Administration (FDA) for its Abbreviated New Drug
Application (ANDA) for Methocarbamol Injection, which is indicated
as an adjunct to rest, physical therapy, and other measures for the
relief of discomfort associated with acute, painful musculoskeletal
conditions. Mylan's immediate shipment of this product supports the
growth of the company's portfolio of more than 100 injectable
products in the U.S.
Methocarbamol Injection USP, 100 mg/mL, had U.S. sales of
approximately $15.1 million for the
12 months ending September 30, 2014,
according to IMS Health.
Currently, Mylan has 286 ANDAs pending FDA approval representing
$111.6 billion in annual brand sales,
according to IMS Health. Forty-five of these pending ANDAs are
potential first-to-file opportunities, representing $29.5 billion in annual brand sales, for the 12
months ending June 30, 2014,
according to IMS Health.
Mylan is a global pharmaceutical company committed to setting
new standards in health care. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several
brand medications. In addition, we offer a wide range of
antiretroviral therapies, upon which approximately 40% of HIV/AIDS
patients in developing countries depend. We also operate one of the
largest active pharmaceutical ingredient manufacturers and
currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated
to improving the customer experience and increasing pharmaceutical
access to consumers around the world. Learn more at mylan.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-robaxin-injection-300008428.html
SOURCE Mylan Inc.